MDXG MiMedx Group Inc.

MIMEDX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MiMedx Group, Inc. - MDXG

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into MiMedx Group, Inc. (NASDAQ: MDXG).

On December 15, 2016, a lawsuit was filed against MiMedx and its CEO Parker Petit by two former employees, alleging that, since 2014, the Company engaged in a fraudulent revenue recognition scheme orchestrated by MiMedx’s executive leadership, including Petit, in order to artificially inflate quarterly revenue and deceive investors. The lawsuit further alleged that, when the former employees internally reported and opposed the fraud, they were immediately retaliated against with threats, intimidation, and termination after a retaliatory investigation.

KSF’s investigation is focusing on whether MiMedx’s officers and/or directors breached their fiduciary duties to MiMedx’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of MiMedx shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]).

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
22/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®...

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States. RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors,...

 PRESS RELEASE

MIMEDX Announces Publication in the Journal of Inflammation Focused on...

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated human amnion chorion membrane (DHACM...

 PRESS RELEASE

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”) Publication Adds to Large Compendium of Evidence for MIMEDX’s Leading Product Portfolio Trial Enrollment Ongoing MARIETTA, Ga., Nov. 13, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial (“RCT”) designed to...

 PRESS RELEASE

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16th Annual Alpha Select Conference | New York, NYTuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NYThursday, November 20, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their resp...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch